Diverse young girls smiling .png

PR Newswire - 23 November, 2020

- Developing STING Antagonist for Treatment of Severe Lupus

- New Investment by Novo Holdings 



ISD-Immunotech is developing a first-in-class therapy to treat the most severe Systemic lupus erythematosus (SLE)  patients. The therapy works by dampening the action of an intracellular protein called STimulator of INterferon Genes (STING). STING is part of the innate immune system, the body’s first line of defense against pathogen invaders like bacteria and viruses. When activated, STING ramps up production of inflammatory proteins called interferons and cytokines. STING overactivity has recently been linked to severe SLE. SLE is an autoimmune disease that can affect any organ of the body including the skin, joints, heart, kidneys, lungs, nervous system and others. As immune cells attack the body, inflammation, scarring, and permanent damage ensue, leading to worsened function and sometimes even organ failure and death.

nephritis IHC.jpg

Today there is no drug that can significantly alter the disease for severe SLE patients.  ISD has shown that our lead prevents the development of SLE in a mouse model of SLE and reduces the interferon signature in a benchtop test of human patient blood samples.  ISD-Immunotech's approach is unique in targeting STING, a new molecular target for SLE, eliciting dampening of multiple events implicated in SLE including IFN-1 levels, other cytokines and apoptosis for broader efficacy. Furthermore, ISD seeks to reduce the complexity of SLE clinical development by using a benchtop test to pre-select severe patients who respond the therapy instead of targeting the heterogenous SLE population. 

SLE hand.jpg

Executive Management

Board of Directors

Ingelise Saunders Chairman of the Board

  • Grey LinkedIn Icon

Lars Jørgen Østergaard 

Founder and Board Member 

Aarhus university_edited.jpg

Alejandra Mørk 


Board Member

  • Grey LinkedIn Icon

Jeroen Bakker 

Board Member

  • Grey LinkedIn Icon

The Team

Tara Heitner


  • Grey LinkedIn Icon

Kristian Hansen


  • Grey LinkedIn Icon

Claus Hansen


  • Grey LinkedIn Icon

Scientific Advisory Board

    Prof. Søren Riis Paludan Chariman of SAB

    Professor in Molecular Virology and immunology, 

    Dept. Biomedicine, Aarhus University, Denmark


    Prapaporn Pisitkun

    Associate Professor at Faculty of Medicine Ramathibodi 

    SAB Member

    • Grey LinkedIn Icon

    Prof. Betty Diamond

    SAB Member

    Professor & Head, Center for Autoimmune, Musculoskeletal & Hematopoietic Diseases 

    The Feinstein Institute for Medical Research

    Professor, Molecular Medicine & Medicine, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell

    • Feinstein Institute_edited


    Scientific Papers 

    Articles by Betty Diamond

    Articles by Søren Riis Paludan

    Galecto9c_Tara Heitner.jpg

    About iSD Immunotech

    iSD Immunotech is a spin-out of Aarhus University, Denmark and is dedicated to developing the first efficacious treatment - a targeted molecular therapy for the most severe SLE patients.

    Contact Us

    To learn more, don't hesitate to get in touch! 


    © 2020 - 2021 iSD Immunotech - Design By SDConsulting-UX Designer